This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Eisai Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Haruo Naito

Algemeen directeur

JP¥127.0m

Totale compensatie

Percentage CEO-salaris	70.1%
Dienstverband CEO	19.7yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	1.1yrs
Gemiddelde ambtstermijn bestuur	2.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Haruo Naito's beloning veranderd ten opzichte van Eisai's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2022	n/a	n/a	JP¥32b
Jun 30 2022	n/a	n/a	JP¥33b
Mar 31 2022	JP¥127m	JP¥89m	JP¥48b
Dec 31 2021	n/a	n/a	JP¥57b
Sep 30 2021	n/a	n/a	JP¥63b
Jun 30 2021	n/a	n/a	JP¥60b
Mar 31 2021	JP¥125m	JP¥89m	JP¥42b
Dec 31 2020	n/a	n/a	JP¥94b
Sep 30 2020	n/a	n/a	JP¥121b
Jun 30 2020	n/a	n/a	JP¥125b
Mar 31 2020	JP¥157m	JP¥89m	JP¥122b
Dec 31 2019	n/a	n/a	JP¥97b
Sep 30 2019	n/a	n/a	JP¥58b
Jun 30 2019	n/a	n/a	JP¥73b
Mar 31 2019	JP¥152m	JP¥89m	JP¥63b
Dec 31 2018	n/a	n/a	JP¥64b
Sep 30 2018	n/a	n/a	JP¥66b
Jun 30 2018	n/a	n/a	JP¥54b
Mar 31 2018	n/a	n/a	JP¥52b
Dec 31 2017	n/a	n/a	JP¥29b
Sep 30 2017	n/a	n/a	JP¥30b
Jun 30 2017	n/a	n/a	JP¥29b
Mar 31 2017	JP¥145m	JP¥89m	JP¥39b
Dec 31 2016	n/a	n/a	JP¥55b
Sep 30 2016	n/a	n/a	JP¥72b
Jun 30 2016	n/a	n/a	JP¥69b
Mar 31 2016	JP¥162m	JP¥89m	JP¥55b

Compensatie versus markt: Haruo's total compensation ($USD975.89K) is below average for companies of similar size in the US market ($USD12.57M).

Compensatie versus inkomsten: Haruo's compensation has been consistent with company performance over the past year.

CEO

Haruo Naito (75 yo)

19.7yrs

Tenure

JP¥127,000,000

Compensatie

Mr. Haruo Naito has been the Chief Executive Officer of Eisai Co., Ltd. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President and Representative Di...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Haruo Naito	CEO, Representative Corporate Officer & Director	19.7yrs	JP¥127.00m	0.23% $ 40.4m
Gary Hendler	Senior VP & President of EMEA Region	no data	JP¥114.00m	geen gegevens
Lynn D. Kramer	Vice President & Chief Clinical Officer - Alzheimer's Disease and Brain Health	no data	JP¥173.00m	geen gegevens
Yanhui Feng	Senior Vice President	3.1yrs	JP¥124.00m	geen gegevens
Nadeem Sarwar	President	no data	geen gegevens	geen gegevens
Tatsuyuki Yasuno	Senior VP	1.1yrs	geen gegevens	0.0022% $ 395.7k
Kenta Takahashi	Executive VP	no data	geen gegevens	0.0030% $ 535.2k
Yosuke Akita	VP, Chief Compliance Officer & Chief Information Security Officer	1.1yrs	geen gegevens	0.00055% $ 97.1k
Sayoko Sasaki	Vice President of Corporate Communications & ESG	1.1yrs	geen gegevens	0.0027% $ 484.0k
Teruyuki Masaka	VP & Chief HR Officer	1.1yrs	geen gegevens	0.00055% $ 97.1k
Yasushi Okada	Representative Corporate Officer	no data	geen gegevens	0.0090% $ 1.6m
Takashi Owa	Senior VP & Chief Scientific Officer - Japan and Asia Medical Safety	no data	geen gegevens	0.0035% $ 616.4k

1.1yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: ESAL.Y's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Haruo Naito	CEO, Representative Corporate Officer & Director	8.7yrs	JP¥127.00m	0.23% $ 40.4m
Yasuhiko Katoh	Independent Chairman	6.7yrs	geen gegevens	0.00052% $ 91.8k
Shuzo Kaihori	Independent Outside Director	4.7yrs	geen gegevens	0.00021% $ 37.1k
Fumihiko Ike	Independent Outside Director	1.7yrs	geen gegevens	0.00035% $ 61.8k
Hideki Hayashi	Director	3.7yrs	geen gegevens	0.013% $ 2.3m
Hideyo Uchiyama	Independent Outside Director	4.7yrs	geen gegevens	0.00021% $ 37.1k
Ryota Miura	Independent Outside Director	1.7yrs	geen gegevens	0.000090% $ 15.9k
Hiroyuki Kato	Director	less than a year	geen gegevens	0.0018% $ 312.6k
Yoshiteru Kato	Director	1.7yrs	geen gegevens	0.0037% $ 657.1k
Yumiko Miwa	Independent Outside Director	2.7yrs	geen gegevens	0.00019% $ 33.6k
Richard Thornley	Director	less than a year	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: ESAL.Y's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

This company listing is no longer active

Eisai Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Recent updates

Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan

Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease

Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan

Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Eisai Initiates BLA Submission of Data for Lecanemab in China

Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference

Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting

DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai.

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer

Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab

Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022

Eisai Presents New Data for Lecanemab (Ban2401) At Alzheimer's Association International Conference

Merck & Co., Inc. and Eisai Co., Ltd. Provides Update on Phase 3 LEAP-002 Trial

Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepted the Biologics License Application

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Co., Ltd., Annual General Meeting, Jun 17, 2022

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway

Eisai Co., Ltd. Announces Article About Long-Term Health Outcomes of Its Investigational Anti-Amyloid-Beta Protofibril Antibody Lecanemab in People Living

Eisai Co., Ltd. to Report Q2, 2023 Results on Nov 07, 2022

Eisai Co., Ltd. (TSE:4523) acquired an unknown minority stake in Arteryex Co., Ltd.

Eisai Co., Ltd. and Biogen Inc. Initiate A Submission to the Pharmaceuticals and Medical Devices Agency of Application Data Under the Prior Assessment Consultation System in Japan for the Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Biogen Inc. and Eisai Co., Ltd. Provides Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM

Eisai Co., Ltd. Announces Dominantly Inherited Alzheimer Network Trials Unit Enrolls the First Subject in the Phase II/III Study

Biogen Inc. and Eisai Company, Ltd. Announces Japan’S Ndc of the Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains Under Review

Biogen Inc. and Eisai Co., Ltd. Announces Update on Regulatory Submission for Aducanumab in the European Union

Eisai Presents Final Results of Phase IV Elevate Study of Anti-Epileptic Drug FYCOMPA® (perampanel) at the American Epilepsy Society 2021 Annual Meeting

Eisai Co., Ltd. to Present Real-World Evidence And Convulsive Seizure Freedom Data Evaluating FYCOMPA® (perampanel) Across Patient Types At 75th American Epilepsy Society (AES) Annual Meeting

Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway

BioArctic AB's partner Eisai Initiates Rolling Submission for the US FDA Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

Eisai Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022

Eisai Co., Ltd. Announces That It Has Obtained Manufacturing and Marketing Approval for the Ezh2 Inhibitor "Tazverik® Tablets 200 Mg" with the Indication of Relapsed or Refractory Ezh2 Gene Mutation-Positive Follicular Lymphoma

Biogen and Eisai, Co., Ltd. Announces FDA Approval for Aduhelm as the First and Only Alzheimer’S Disease Treatment to Address A Defining Pathology of the Disease

Eisai Announces Real-World Data on the Effectiveness of HALAVEN® (eribulin mesylate) for the Treatment of Patients with Metastatic Breast Cancer (mBC) Published in Advances in Therapy

Eisai Co., Ltd. Announces Dividend for the Year Ended March 31, 2021, Payable on May 21, 2021; Provides Dividend Guidance for the Year Ending March 31, 2022

Merck and Eisai Receive Priority Review from FDA for Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) Applications for Advanced Renal Cell Carcinoma and for Advanced Endometrial Carcinoma

Eisai Co., Ltd. to Report Q3, 2022 Results on Feb 03, 2022

Bioarctic and Eisai Present Latest Data Regarding Lecanemab at AD/PD 2021

Bioarctic AB (Publ) and Eisai to Present Data Relating to Its Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody Lecanemab (BAN2401)

Eisai Co., Ltd. Revises Consolidated Earnings Guidance for the Full Year Ending March 31, 2021

Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab

Eisai Co., Ltd. to Present Abstracts on Lenvatinib at 2021 Gastrointestinal Cancers Symposium

Biogen and Eisai, Co., Ltd. Files New Drug Application for Aducanumab in Japan

Eisai Co., Ltd. Announces Presentations on A Series of Abstracts Highlighting Updates on Its In-House Discovered Lenvatinib Mesylate Lenvima

Eisai Co., Ltd. and Wren Therapeutics Ltd. Enter into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

Eisai Announces New Investigational Data from Study 211 Evaluating the Starting Dose of Lenvima

BioArctic AB (publ) Partner Eisai Presents Latest Data Regarding Drug Candidate BAN2401 at CTAD 2020

Eisai Announces Investigational Data Highlighting Lenvima® (Lenvatinib) Based Combination Therapy in Patients with Renal Cell Carcinoma At IKCS 2020

European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease

Global Coalition for Adaptive Research, Amgen, and Eisai Announce First Patient Enrolled in International Covid-19 Trial

Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, A Treatment of Osteoarthritis, in South Korea

Merck and Eisai Present First-Time Data from Two Studies Evaluating Keytruda® (Pembrolizumab) Plus Lenvima® (Lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020

Eisai Co., Ltd. Announces the Latest Results from the Cohort Targeting Patients with HER2-Negative Breast Cancer in the Phase I Clinical Trial for the New Liposomal Formulation (E7389-LF)

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd